Mallinckrodt plc Files 8-K
| Field | Detail |
|---|---|
| Company | Mallinckrodt PLC |
| Form Type | 8-K |
| Filed Date | Oct 24, 2025 |
| Risk Level | low |
| Pages | 12 |
| Reading Time | 14 min |
| Key Dollar Amounts | $0.001, $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, filing, financials
TL;DR
MNK filed an 8-K on Oct 24 for events on Oct 21 - other events & financials.
AI Summary
Mallinckrodt plc filed an 8-K on October 24, 2025, reporting on events that occurred on October 21, 2025. The filing indicates "Other Events" and "Financial Statements and Exhibits" as key items. The company is incorporated in Ireland and its principal executive offices are located in Dublin.
Why It Matters
This 8-K filing provides an update on significant events and financial information for Mallinckrodt plc, which could impact investors and stakeholders.
Risk Assessment
Risk Level: low — This filing is a routine 8-K reporting on events and exhibits, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Mallinckrodt plc (company) — Registrant
- October 21, 2025 (date) — Date of Earliest Event Reported
- October 24, 2025 (date) — Date of Report
- Ireland (location) — State of Incorporation
- Dublin 15, Ireland (location) — Address of principal executive offices
FAQ
What specific "Other Events" are being reported by Mallinckrodt plc in this 8-K?
The filing indicates "Other Events" as an item, but the specific details of these events are not provided in the excerpt.
What is the significance of "Financial Statements and Exhibits" being listed?
This suggests that the filing includes or references financial statements and other relevant exhibits, which are typically important for understanding the company's financial health and operations.
When was Mallinckrodt plc incorporated, and where are its principal executive offices located?
Mallinckrodt plc was incorporated in Ireland, and its principal executive offices are located at College Business & Technology Park, Cruiserath, Blanchardstown, Dublin 15, Ireland.
What is the Commission File Number and IRS Employer Identification No. for Mallinckrodt plc?
The Commission File Number is 001-35803, and the IRS Employer Identification No. is 98-1088325.
What is the SIC code for Mallinckrodt plc?
The Standard Industrial Classification (SIC) code for Mallinckrodt plc is 2834, which corresponds to Pharmaceutical Preparations.
Filing Stats: 3,616 words · 14 min read · ~12 pages · Grade level 17.9 · Accepted 2025-10-24 17:09:32
Key Financial Figures
- $0.001 — outstanding preferred shares, par value $0.001 per share (the " Mallinckrodt Preferred
- $0.01 — er of shares of common stock, par value $0.01 per share, of Par Health (the " Par Hea
Filing Documents
- tm2529406d1_8k.htm (8-K) — 58KB
- tm2529406d1_ex99-1.htm (EX-99.1) — 21KB
- tm2529406d1_ex99-2.htm (EX-99.2) — 63KB
- tm2529406d1_ex99-1img001.jpg (GRAPHIC) — 231KB
- tm2529406d1_ex99-1img002.jpg (GRAPHIC) — 240KB
- tm2529406d1_ex99-1img003.jpg (GRAPHIC) — 250KB
- tm2529406d1_ex99-1img004.jpg (GRAPHIC) — 181KB
- tm2529406d1_ex99-1img005.jpg (GRAPHIC) — 158KB
- tm2529406d1_ex99-1img006.jpg (GRAPHIC) — 78KB
- 0001104659-25-102199.txt ( ) — 1898KB
- mnk-20251021.xsd (EX-101.SCH) — 3KB
- mnk-20251021_lab.xml (EX-101.LAB) — 33KB
- mnk-20251021_pre.xml (EX-101.PRE) — 22KB
- tm2529406d1_8k_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. Spin-off of Par Health On October 21, 2025, the Board of Directors (the " Board ") of Mallinckrodt plc (the " Company " or " Mallinckrodt ") approved resolutions authorizing, in principle, the previously announced plan to spin off (the " Spin-off ") the Company's generic pharmaceuticals, active pharmaceutical ingredients (APIs) and sterile injectables businesses to the Company's shareholders. At the time of the Spin-off, such businesses will be held by Par Health, Inc. (" Par Health "), a Delaware corporation and a wholly owned subsidiary of Mallinckrodt. Par Health will operate as an independent company following the Spin-off and its shares will not be listed on a securities exchange. The Spin-off remains subject to the satisfaction of certain conditions, including, among others, the publication of an information statement (the " Information Statement ") regarding the Spin-off and final approval by the Board. The Information Statement is expected to be furnished with the U.S. Securities and Exchange Commission in the coming days. The Board retains the authority to modify the terms of, or to abandon, the Spin-off at any time and for any reason until it has been consummated, including by accelerating or delaying the timing of the consummation of all or part of the Intended Redemption (as defined below). If approved, the Spin-off will be implemented by way of a redemption (the " Intended Redemption ") of all of Mallinckrodt's issued and outstanding preferred shares, par value $0.001 per share (the " Mallinckrodt Preferred Shares "), comprising 1,796,196,578,472 Mallinckrodt Preferred Shares, upon which the Mallinckrodt Preferred Shares will automatically be cancelled and will no longer be outstanding. At the closing of the Intended Redemption, the Mallinckrodt Preferred Shares will be redeemed in exchange for the following, subject to compliance with the Certification Procedures (as defined below) and the terms of the Intended Redemption
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. The following exhibits are filed as part of this report: Exhibit Number Description 99.1 Sample Certification Form. 99.2 Notice of Intention to Redeem, dated October 24, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). -5- Information Regarding Forward-Looking Statements that are not strictly historical may be "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995, and involve a number of risks and uncertainties. There are a number of important factors that could cause actual events to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include risks and uncertainties related to, among other things: the expected benefits and synergies of the business combination with Endo, Inc. ("Business Combination") may not be fully realized in a timely manner, or at all; risks related to Mallinckrodt's increased indebtedness as a result of the Business Combination and significant transaction costs related to the Business Combination; uncertainties related to a future separation of the combined generics pharmaceuticals businesses and sterile injectables business including the risk that the separation may not occur on a timely basis or at all; potential changes in Mallinckrodt's business strategy and performance; exposure to global economic conditions and market uncertainty; the exercise of contingent value rights by the Opioid Master Disbursement Trust II; governmental investigations and inquiries, regulatory actions, and lawsuits, in each case related to Mallinckrodt or its officers; Mallinckrodt's contractual and court-ordered compliance obligations that, if violated, could result in penalties; compliance with and restrictions under the global settlement
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. MALLINCKRODT PLC Date: October 24, 2025 By: /s/ Mark Tyndall Name: Mark Tyndall Title: Executive Vice President and Chief Legal Officer & Corporate Secretary -7-